Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Indexado en
  • Índice Copérnico
  • Google Académico
  • Búsqueda de referencia
  • Directorio de indexación de revistas de investigación (DRJI)
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • director académico
  • Fundación de Ginebra para la educación y la investigación médicas
  • Pub Europeo
Comparte esta página

Abstracto

Mono or Dual-Ligand Nanoparticles: Theoretical Study

Ebtisam A Aldaais*

Dual-ligand nanocarriers have been developed to target over-expressed receptors, such as epidermal growth factor receptors (EGFR) and folate receptors (FR), in cancer cells. The dual ligand technique has been developed to enhance nanocarrier targeting, by binding to two kinds of over-expressed receptors instead of one. This study theoretically designs the binding of dual-ligand to two types of over-expressed receptors on cancer cells. We developed molecular theory that considers van der Waals, steric, and electrostatic interactions under a decoupled self-consistent field (SCF) approach. Our developed theory determines the dual-ligand-receptor binding regulations, and it can be applied for triple-ligand nanocarriers. The developed theory shows that dual-ligand nanocarriers are more effective than two mono-ligand nanocarriers combined. Manipulating some of the environmental parameters, such as salt concentration, temperature, and pH, along with the design parameters, such as polyelectrolytes pKa, number of polymers, and their density, can improve the functionality of the therapeutic nanocarriers. Besides, the size of the targeted nanocarriers is determined in this work to an efficient binding to two or more receptors on the cancer cell.